---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-21-034761"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2021-10-18T23:59:59+00:00"
generated_at: "2026-06-28T20:14:26.042326+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics adds former Momenta CFO/CO Young T. Kwon to Board

## Summary
- Dr. Kwon appointed as Class II director with term through 2024 annual meeting.
- Previously served as CFO/CO at Momenta, leading its $6.5B sale to Johnson & Johnson in 2020.
- Will receive an initial grant of options to purchase 93,500 shares of common stock.
- Currently an operating partner at Lightstone Ventures, assisting with deal sourcing and portfolio management.
- Brings over a decade of strategic, financial, and business development experience in biotech.

## SEC filing metadata
- accession: 0001140361-21-034761
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2021-10-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036121034761/0001140361-21-034761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036121034761/brhc10029850_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-21-034761
- JSON: https://secwatch.observer/filing/0001140361-21-034761.json
- Plain text: https://secwatch.observer/filing/0001140361-21-034761.txt

## Key facts
- Executive change
  Young T. Kwon was appointed as Class II director at ADMA BIOLOGICS, INC..
  - Action: appointed
  - Role: Class II director
  source text: On October 15, 2021, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Young T. Kwon, Ph.D. to serve on the Board as a Class II director with a term expiring at the Company’s 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036121034761/0001140361-21-034761-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.